MRK.VI Merck & Company Inc

Healthcare Pharmaceuticals Vienna Exchange
132.66 EUR
Close of Oct 29, 2026
70.05 136.24
Market cap
EUR 330B
P/E
122.8x
P/B
8.22x
ROE
-26.6%
Dividend yield
2.28%
Fundamental score
1.8/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MRK.VI undervalued?

Graham number

The Graham number of Merck & Company Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Merck & Company Inc fundamental analysis

8 of 21 checks passed

ROE 0/2

Low return on equity (-26.6%), below 10%.

ROA 0/1

Return on assets (-8.6%) is below the industry median (3.8%).

Profit Consistency 2/2

Profitable for 6 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (8.9%) is not above the 5-year average (21.4% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (8.9%) is below the industry median (14.7%).

Revenue Growth 1/2

Revenue grew 3.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (121.8%), above 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Loss-making but free cash flow is positive.

PE vs Market 0/1

PE (123.8x) is above the market median (18.5x).

PE vs Industry 0/1

PE (123.8x) is above the industry median (16.6x).

PBV 0/1

Price to book (8.3x) is above the industry median (1.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 1,025.8, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 5.77, above 1.

Dividend Yield 0/2

Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.

Dividend Stability 1/2

Dividends paid without a cut of more than 10% for 6 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 44.8%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Merck & Company Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Merck & Company Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccine…

Full company profile